United Therapeutics (UTHR)

Executive Summary

United Therapeutics is a biotechnology company focused on innovative therapies for pulmonary arterial hypertension (PAH) and regenerative medicine, including xenotransplantation. The company has a strong commercial portfolio of PAH drugs, generating significant revenue, and is advancing a pipeline of early-stage programs. Key areas include inhaled treprostinil (Tyvaso) and oral treprostinil, which have been approved and are expanding into new indications. In regenerative medicine, United Therapeutics is pioneering xenotransplantation with genetically modified pig organs, potentially addressing the organ shortage crisis. The company's robust financials and diversified pipeline support a solid long-term outlook, though risk remains with early-stage and unproven technologies.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on expanded indication for Tyvaso DPI in pulmonary hypertension80% success
• Q2 2027Phase 1 data from DT2216 combination trial in ovarian cancer40% success
• H1 2027Update on xenotransplantation clinical program (first human transplant results)30% success